News + Filings Holdings
All
13F
13D/G
Other
|
|
CAXTON CORP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 5% stake in Rezolute, Inc. |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 2.2% stake in Cardiff Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 0.9% stake in Addex Therapeutics Ltd |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 4.4% stake in Xeris Biopharma Holdings, Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/12/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 8.1% stake in Cardiff Oncology, Inc. |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 9% stake in SCYNEXIS, Inc. |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 6% stake in Addex Therapeutics Ltd |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 8.6% stake in Rezolute, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| CAXTON CORP reports a 6.1% stake in Savara Inc. |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/05/2022 |
SC 13D/A
| CAXTON CORP reports a 0% stake in Strongbridge Biopharma plc |
| 01/05/2022 |
4
| CDK ASSOCIATES, L.L.C. (10% Owner) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed of 8,060,682 shares
@ $0
Disposed of 2,220,000 options to buy
@ $2.5, valued at
$5.6M
|
|
| 01/05/2022 |
SC 13G
| CAXTON CORP reports a 5.7% stake in Xeris Biopharma Holdings, Inc. |
| 11/15/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/16/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/17/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 03/19/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/16/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/14/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|
|
|